Outset Medical prelim Q4 rev $28.9M; FY2025 rev $119.5M (+5% YoY); cash $173M; appoints Prange

Outset Medical, Inc.

2025-FY EPS reported -$5.37 revenue$119,476,000

Q4 2025 revenue ~$28.9M; full-year 2025 revenue $119.5M, up 5% from $113.7M in 2024.
Year-end cash (incl. restricted cash & short-term investments) $173M; net cash used in ops <$50M vs $116M in 2024.
Over 1,000 sites insource dialysis with Outset; ~1M treatments/year; cumulative >3M treatments on Tablo.
Andrea Saia resigned from board effective Jan 9, 2026; Karen Prange appointed to board and Compensation Committee.
Prange brings med device exec experience (Henry Schein, Boston Scientific, Johnson & Johnson).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.